Can Aromatase Inhibitor therapy increase dry eye symptoms in postmenopausal women?
In a recent study by PI Pauline Khoo and peers found that longer duration of aromatase inhibitor (AI) therapy and higher tear osmolarity can increase the risk for dry eye in postmenopausal women. The extensive study was published in the Nature's Eye Journal.
Dry eyes are a prominent source of discomfort and treatment non-compliance in women on aromatase inhibitor (AI) therapy for breast cancer. However, nothing is known about how it affects the ocular surface. As a result, the study was proposed to test if the symptomatic dry eye in AI patients is associated with the clinical features of evaporative dry eye.
An observational cross-sectional investigation of postmenopausal women treated with AI was carried out. Clinical data was obtained from their treating clinician. Validated questionnaires were used to measure ocular and treatment symptoms. Clinical examinations were carried out to determine the presence of dry eyes. This study's major outcome measure was dry eye symptoms as determined by questionnaire. Clinical indications of dry eye and hormone levels were used as secondary outcome indicators.
The results of this study stated as follow:
1. On AI, a total of 25 ladies were recruited.
2. Dry eye symptoms were reported by 64% of women (ocular surface disease index 13).
3. When symptomatic dry eye patients were compared to asymptomatic individuals, they had higher tear osmolarity (323 vs 307 mOsm/L, p = 0.002) and more meibomian gland dropout (4 vs 1, p = 0.002).
4. The use of AI for a longer period of time and higher tear osmolarity increased the risk of a patient suffering dry eye symptoms, according to multivariate logistic regression.
In conclusion, with the rising frequency of breast cancer and a growing number of patients receiving AI therapy for an extended period of time, patients should be evaluated for tear film stability on a regular basis and advised on the likelihood of developing dry eye condition.
Reference:
Khoo, P., Groeneveld, T., Boyle, F., O'Neill, S., Forster, B., & Watson, S. L. (2021). Dry eye signs and symptoms in patients on aromatase inhibitor therapy. In Eye (Vol. 36, Issue 4, pp. 766–772). Springer Science and Business Media LLC. https://doi.org/10.1038/s41433-021-01538-6
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.